Document ID: chunk:federal_register_of_legislation:F2025L00212:clause:1_3322
Version: federal_register_of_legislation:F2025L00212
Segment Type: clause
Provision Reference: sch 1 cl 3322
Character Range: 1548606–1549975

3322                                      METHYL HYDROJASMONATE                                                                         E         The route(s) of administration for medicines that contain methyl hydrojasmonate must be limited to:
                                                                                                                                                  (a) topical for dermal use; and
                                                                                                                                                  (b) oral.
                                                                                                                                                  When used in oral medicines:
                                                                                                                                                  (a) methyl hydrojasmonate must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation; and
                                                                                                                                                  (b) the total concentration of flavour proprietary excipient formulations containing methyl hydrojasmonate must not be more than 5% of the total medicine.